RBM41 (Gene)

Synonyms:ENTREZ:55285, HGNC:25617, NM_001171080, NM_001324242, NM_001324243, NM_001324244, NM_001394116, NM_001394117, NM_001394118, NM_001394119, NM_001394120, NM_001394121, NM_001394122, NM_001394123, NM_001394124, NM_001394125, NM_001394126, NM_001394127, NM_018301, NP_001164551, NP_001311171, NP_001311172, NP_001311173, NP_001381045, NP_001381046, NP_001381047, NP_001381048, NP_001381049, NP_001381050, NP_001381051, NP_001381052, NP_001381053, NP_001381054, NP_001381055, NP_001381056, NP_060771, NR_136728, NR_136729, NR_136730, NR_136731, NR_136732, RBM41, RNA binding motif protein 41, XM_011530980, XM_011530981, XP_011529282, XP_011529283
Id:ENSG00000089682
Entrez:55285
Description:RNA binding motif protein 41
Predicted to enable U12 snRNA binding activity and pre-mRNA intronic binding activity. Predicted to be involved in mRNA splicing, via spliceosome. Predicted to be part of U12-type spliceosomal complex. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View RBM41's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with RBM41.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using RBM41.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for RBM41.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with RBM41.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.